Skip to main content
SpringerLink
Log in

Radiotherapy for Ductal Cancer In Situ (DCIS) of the Breast

  • Living reference work entry
  • First Online:
Book cover Radiation Oncology

  • 231 Accesses

Abstract

Ductal carcinoma in situ (DCIS) is a non-invasive precursor of invasive breast cancer. Due to the introduction of mammography screening in many countries, its detection rate has increased considerably. Adjuvant whole-breast radiotherapy is highly efficient in reducing the risk of ipsilateral invasive and non-invasive recurrences without a benefit in overall survival. This chapter discusses the relevant literature regarding the interdisciplinary management of DCIS as well as the role of radiotherapy and recent developments such as hypofractionation, boost irradiation and accelerated partial breast irradiation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;2010(41):134–8.

    Article  Google Scholar 

  • Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73.

    Article  CAS  Google Scholar 

  • Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443–8.

    Article  Google Scholar 

  • Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol. 2013;14(9):e348–57.

    Article  Google Scholar 

  • Cheung S, Hendy GN, Lagard C, Williams L, Kearins O, Lawrence G. All breast cancer report. A UK analysis of all symptomatic an screen-detected breast cancer diagnosed in 2006. 2006. http://www.ncin.org.uk/view?rid=68, NHS Cancer Screening Programmes.

  • Childs SK, Chen YH, Duggan MM, Golshan M, Pochebit S, Punglia RS, Wong JS, Bellon JR. Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2013;85(4):948–52.

    Article  Google Scholar 

  • Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, White J, Harris JR. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7(2):73–9.

    Article  Google Scholar 

  • Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21–9.

    Article  CAS  Google Scholar 

  • D’Orsi C. Radiology. ACR BI-RADS Atlas: breast imaging reporting and data system. 2013.

    Google Scholar 

  • Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, Bijker N. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054–9.

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative, G, Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162–77.

    Article  Google Scholar 

  • Edge S. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  • Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, Pijnappel RM, Bijker N, Rutgers EJ, Wesseling J. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – the LORD study. Eur J Cancer. 2015;51(12):1497–510.

    Article  Google Scholar 

  • Fitzgibbons PL, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ (DCIS) of the breast (Version 4.1.0.0). College of American Pathologists; January 2018. Accessed on 19 July 2018; Available at www.cap.org/cancerprotocols.

  • Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013;20(13):4103–12.

    Article  Google Scholar 

  • Foote FW Jr, Stewart FW. A histologic classification of carcinoma of the breast. Surgery. 1946;19:74–99.

    PubMed  Google Scholar 

  • Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J, investigators I-I. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387(10021):866–73.

    Article  CAS  Google Scholar 

  • Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, Roberts T, Pirrie S, Gaunt C, Young J, Billingham L, Dodwell D, Hanby A, Pinder SE, Evans A, Reed M, Jenkins V, Matthews L, Wilcox M, Fairbrother P, Bowden S, Rea D. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51(16):2296–303.

    Article  Google Scholar 

  • Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2013;11:CD000563.

    Google Scholar 

  • Gorringe KL, Fox SB. Ductal carcinoma in situ biology, biomarkers, and diagnosis. Front Oncol. 2017;7:248.

    Article  Google Scholar 

  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  Google Scholar 

  • Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 1990;335(8688):519–22.

    Article  CAS  Google Scholar 

  • Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA editors. SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda. Based on November 2016 SEER data submission, posted to the SEER web site, April 2017. 2016. https://seer.cancer.gov/csr/1975_2014/.

  • Jacklyn G, Morrell S, McGeechan K, Houssami N, Irwig L, Pathmanathan N, Barratt A. Carcinoma in situ of the breast in New South Wales, Australia: current status and trends over the last 40 year. Breast. 2018;37:170–8.

    Article  Google Scholar 

  • Krug D, Souchon R. Radiotherapy of ductal carcinoma in situ. Breast Care (Basel). 2015;10(4):259–64.

    Article  Google Scholar 

  • Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R. Current controversies in radiotherapy for breast cancer. Radiat Oncol. 2017;12(1):25.

    Article  Google Scholar 

  • Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL, Smith BL, Weaver DL, Winer E. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009;133(1):15–25.

    PubMed  Google Scholar 

  • Lesurf R, Aure MR, Mork HH, Vitelli V, Lundgren S, Borresen-Dale AL, Kristensen V, Warnberg F, Hallett M, Sorlie T. Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer. Cell Rep. 2016;16(4):1166–79.

    Article  CAS  Google Scholar 

  • Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J. Clinical utility of the 12-gene DCIS score assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Ann Surg Oncol. 2017;24(3):660–8.

    Article  Google Scholar 

  • Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387(10021):849–56.

    Article  CAS  Google Scholar 

  • Martins D, Sousa B, Lopes N, Gomes M, Veronese L, Albergaria A, Paredes J, Schmitt F. Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Hum Pathol. 2011;42(10):1438–46.

    Article  CAS  Google Scholar 

  • McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W Jr, Pu AT, Kerlin K, White J. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709–15.

    Article  CAS  Google Scholar 

  • Merrill AL, Tang R, Plichta JK, Rai U, Coopey SB, McEvoy MP, Hughes KS, Specht MC, Gadd MA, Smith BL. Should new “no ink on tumor” lumpectomy margin guidelines be applied to ductal carcinoma in situ (DCIS)? A retrospective review using shaved cavity margins. Ann Surg Oncol. 2016;23(11):3453–8.

    Article  Google Scholar 

  • Moran MS, Zhao Y, Ma S, Kirova Y, Fourquet A, Chen P, Hoffman K, Hunt K, Wong J, Halasz LM, Freedman G, Prosnitz R Jr, Yassa M, Nguyen DHA, Hijal T, Haffty BG, Wai ES, Truong PT. Association of Radiotherapy Boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol. 2017;3(8):1060–8.

    Article  Google Scholar 

  • Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol. 2016;34(33):4040–6.

    Article  Google Scholar 

  • Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, Liao LM, Love J, Brinton LA, Gierach GL. Epidemiologic risk factors for in situ and invasive breast cancers among postmenopausal women in the National Institutes of Health-AARP diet and health study. Am J Epidemiol. 2017;186(12):1329–40.

    Article  Google Scholar 

  • Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888–96.

    Article  Google Scholar 

  • Nilsson C, Valachis A. The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol. 2015;114(1):50–5.

    Article  Google Scholar 

  • Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat. 2018;169:359–369.

    Article  CAS  Google Scholar 

  • Rashtian A, Iganej S, Amy Liu IL, Natarajan S. Close or positive margins after mastectomy for DCIS: pattern of relapse and potential indications for radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(4):1016–20.

    Article  Google Scholar 

  • Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9.

    Article  Google Scholar 

  • Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, DeSantis S, Barry WT, Golshan M. Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study. J Clin Oncol. 2016;34(11):1190–6.

    Article  CAS  Google Scholar 

  • Shah C, Vicini F, Shaitelman SF, Hepel J, Keisch M, Arthur D, Khan AJ, Kuske R, Patel R, Wazer DE. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018;17(1):154–70.

    Article  Google Scholar 

  • Silverstein MJ, Lagios MD. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J. 2015;21(2):127–32.

    Article  Google Scholar 

  • Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.

    Article  CAS  Google Scholar 

  • Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33(33):3938–44.

    Article  Google Scholar 

  • Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ: cochrane systematic review and meta-analysis. Breast. 2014;23(5):546–51.

    Article  CAS  Google Scholar 

  • Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ. Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol. 2015;22(10):3273–81.

    Article  Google Scholar 

  • van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ. Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer. 2013;49(16):3517–25.

    Article  Google Scholar 

  • Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;262(4):623–31.

    PubMed  PubMed Central  Google Scholar 

  • Vapiwala N, Hwang WT, Kushner CJ, Schnall MD, Freedman GM, Solin LJ. No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy. Cancer. 2017;123(8):1324–32.

    Article  Google Scholar 

  • Vicini F, Shah C, Ben Wilkinson J, Keisch M, Beitsch P, Lyden M. Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI. Ann Surg Oncol. 2013;20(4):1275–81.

    Article  Google Scholar 

  • Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–8.

    Article  Google Scholar 

  • Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.

    Article  Google Scholar 

  • Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, Brawley OW, Gansler T. Cancer statistics: breast cancer in situ. CA Cancer J Clin. 2015;65(6):481–95.

    Article  Google Scholar 

  • Warnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, Ringberg A, Karlsson P, Arnesson LG, Anderson H, Jirstrom K, Holmberg L. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol. 2014;32(32):3613–8.

    Article  Google Scholar 

  • Wong JS, Chen YH, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Smith BL, Troyan SL, Harris JR. Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat. 2014;143(2):343–50.

    Article  Google Scholar 

  • Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, Myers ER, Hwang ES. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst. 2015;107(12):djv263.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany

    David Krug

  2. Department of Radiation Oncology, University Hospital Schleswig-Holstein, Kiel, Kiel, Schleswig-Holstein, Germany

    René Baumann

  3. Department of Radiation Oncology, St. Marienkrankenhaus, Siegen, Germany

    René Baumann

Authors
  1. David Krug
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. René Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Krug .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University Hospital Mannheim, Mannheim, Germany

    Frederik Wenz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Krug, D., Baumann, R. (2018). Radiotherapy for Ductal Cancer In Situ (DCIS) of the Breast. In: Wenz, F. (eds) Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-52619-5_58-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52619-5_58-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52619-5

  • Online ISBN: 978-3-319-52619-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation